Remove some of the pain from translating your IP and take advantage of our developmental capabilities
What we do
We bridge the gap between academic research and commercial product development by identifying, protecting, partnering and commercialising intellectual property. MRCT has considerable experience in managing and exploiting the intellectual property arising from academic work from the UK’s Medical Research Council.
Our IP and expertise has been acquired by all of the world’s leading pharmaceutical companies and we have participated in the creation of 18 start-ups including the UK’s largest and most successful biotech companies; Celltech (now part of UCB) and Cambridge Antibody Technology (CAT; now part of AstraZeneca).
We have also established IP collaborations with other TTOs. For example we have an agreement with MBM ScienceBridge to exploit IP from Georg-August-University Göttingen and the University of Regensburg. Here a mouse antibody will be humanised, in our Centre for Therapeutics Discovery antibody humanization programme, to create a potential new therapy for inflammatory and immune diseases.
What we can do for you
Our Business Development team could audit your research portfolio to identify any IP that could be protected and commercialised to generate income for your organisation and to benefit public health. We could also suggest ways in which the research could be developed including via our Centre for Therapeutics Discovery.
How to work with us
Our way of working is very flexible; we can work with you on preferred partner terms, or on a project-by-project basis.
To find out how MRCT can be of assistance to your organisation please contact us.
News feed
MRCT are collaborating with the University of Bristol to develop orally available small molecule TrkA antagonists for treatment of chronic intractable pain.
MRC Technology’s Therapeutic Antibody Group and The University of Aberdeen work together on project to develop therapeutic against a novel cancer target, soluble CTLA-4.
Aptuscan, a spin out company based on research carried out at the MRC Cancer Cell Unit, has been acquired by Avacta, an AIM-listed biotechnology company.
MRC Technology announced today that they have entered into an agreement with the Association for International Cancer Research (AICR) to assist in the oversight and management of intellectual property (IP) arising from AICR-funded projects.